| Leona J Sedlacek, CNS | |
|
1836 South Ave, La Crosse, WI 54601-5429 | |
| (608) 782-7300 | |
| Not Available |
| Full Name | Leona J Sedlacek |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Neuroscience |
| Location | 1836 South Ave, La Crosse, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699770032 | NPI | - | NPPES |
| 43900200 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SN0800X | Clinical Nurse Specialist - Neuroscience | 1501 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Leona J Sedlacek, CNS 1836 South Ave, La Crosse, WI 54601-5429 Ph: (608) 782-7300 | Leona J Sedlacek, CNS 1836 South Ave, La Crosse, WI 54601-5429 Ph: (608) 782-7300 |
News Archive
The ability of the commonly used stimulant methylphenidate (Ritalin) to speed recovery from general anesthesia appears to apply both to the inhaled gas isoflurane, as previously reported, and to the intravenous drug propofol. Members of the same Massachusetts General Hospital (MGH) research team that reported the isoflurane study are publishing similar results for propofol in the May issue of Anesthesiology, and their paper has been issued online.
Delcath Systems, Inc. announced today that it intends, subject to market and other conditions, to offer up to 8.5 million shares of its common stock in a registered public offering pursuant to its existing shelf registration statement under the Securities Act of 1933. Delcath also intends to grant the underwriters of the offering an option to purchase up to 15% of additional shares of primary stock to cover over-allotments.
A research team, led by an IU School of Health and Rehabilitation faculty member at Indiana University-Purdue University Indianapolis, has determined that adapted yoga is both feasible and beneficial for adults with stroke or traumatic brain injury.
Generex Biotechnology Corporation today announced presentation of additional results from a recently completed Phase I clinical trial of its novel immunotherapeutic peptide AE37 in prostate cancer patients. AE37 is a synthetic cancer vaccine being developed by Antigen Express, Inc., a wholly owned subsidiary of Generex, for multiple cancer indications.
› Verified 5 days ago
Angeline Marie Finch, CNS Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Mindy Rae Zenke, CNS, APNP Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 800 West Ave S, La Crosse, WI 54601 Phone: 608-785-0940 | |
Beckie Jean Kronebusch, APRN, CNS Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 700 West Ave S, La Crosse, WI 54601 Phone: 608-392-9413 | |
Ms. Debra A Day, APNP Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 300 4th St N, La Crosse, WI 54601 Phone: 608-343-2476 | |
Mrs. Erica Rae Neumeister, NP Clinical Nurse Specialist Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-3000 | |
Thomas C Reardon, CNS Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 |